New Frontiers in
the Science and Medicine of
Venous Thromboembolism

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period April 20, 2010 through April 20, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of and strategies for preventing venous thromboembolism in the setting of heart disease, coronary artery disease and pulmonary hypertension .

Release Date:

April 20, 2010

Expiration Date:

April 20, 2012

Intended Audience:

• Thrombosis specialists
• Preventive cardiologists
• Cardiovascular surgeons
• Vascular medicine specialists
• Anticoagulation experts
• Heart failure specialists
• Coronary care unit (CCU) specialists and directors
• Program directors, cardiovascular medicine
• Fellows in cardiovascular medicine
• Clinical pharmacists and pharmacologists
• Pharmacy directors (cardiovascular medicine)
• Investigators and clinical trial specialists
• Cardiovascular nurses

Registration:

Enrollment for this WebCAST WRAP is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant
from sanofi-aventis.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Samuel Z. Goldhaber, MD – Program Chairman and Moderator
Professor of Medicine
Cardiovascular Division
Director, Venous Thromboembolism Research Unit
Harvard Medical School
Brigham and Women’s Hospital
Boston, MA

Research Support: BMS; Boehringer-Ingelheim; Eisai; Johnson and Johnson; Sanofi-Aventis
Consultant: BMS, Boehringer-Ingelheim, Eisai, Medscape, Merck,Pfizer,sanofi-aventis,Vortex


Jon Kobashigawa, MD
Medical Director, UCLA Heart Transplant Program
Co-Chief, Division of Clinical Faculty Medicine
Department of Medicine
UCLA School of Medicine
Los Angeles, CA

Research grants, advisory boards, speaker honoraria: Roche, Novartis, Astellas


Irene Land, MD
Professor of Vascular Biology
Division of Cardiology
Department of Internal Medicine I Medical
University of Vienna
Vienna, Austria

Consulting fees , honoraria, speaker bureau and research support: Actelion, Inc.


Paul Ridker, MD
Eugene Braunwald
Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Woman’s Hospital
Boston, MA

Research Support: NHLBI, NCI, American Heart Association, Donald W Reynolds Foundation, Leduc Foundation, Doris Duke Charitable
Foundation, AstraZeneca, Novartis, and sanofi-aventis.
Consultant: Seimens, AstraZeneca, Vascular Biogenics, Merck, Schering Plough, and Novartis.

Co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and
diabetes licensed to Seimens and AstraZeneca.

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Learn how to optimize prevention and management of VTE in patients with heart failure, CAD, and other CV conditions
• Learn to optimize prevention of VTE in patients with risk factors for coronary artery disease, including patients with obesity, HBP, diabetes, and related conditions
• Learn about evidence-supported management strategies—including established and evolving anticoagulation strategies and statin therapy—that have been shown to provide safe and effective thromboprophylaxis across the arterial and venous risk spectrum in patients with heart disease
• Learn how to manage shared risk factors for patients with VTE and coronary artery disease
• Learn how to evaluate, select among, and appropriately use the range of pharmacologic options currently available for prevention of VTE in patients with HF and CAD, including LMWHs and other agents that are indicated for VTE prophylaxis in the setting of heart disease
• Learn about current national guidelines for prevention of VTE in patients with heart disease and related conditions
• Learn how to employ multimodal management in patients with chronic thromboembolic pulmonary hypertension (CTPH)
• Learn how to prevent VTE and its complications, post-thrombotic syndrome (PTS) in patients with chronic heart failure and pulmonary hypertension
• Learn about the causes, risk factors, mechanisms, landmark trials, practice statements, comparative effectiveness, and therapeutic approaches to preventing and managing the VTE disease state in patients with high-risk heart disease
  

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2011 Resources, LLC All rights reserved.